» Articles » PMID: 23251289

Expression of Intestinal Transporter Genes in Beagle Dogs

Overview
Journal Exp Ther Med
Specialty Pathology
Date 2012 Dec 20
PMID 23251289
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

This study was performed to produce a transcriptional database of the intestinal transporters of beagle dogs. Total RNA was isolated from the duodenum and the expression of various mRNAs was measured using GeneChip(®) oligonucleotide arrays. A total of 124 transporter genes were detected. Genes for fatty acid, peptide, amino acid and glucose and multidrug resistance/multidrug resistance-associated protein (MDR/MRP) transport were expressed at relatively higher levels than the other transporter types. The dogs exhibited abundant mRNA expression of the fatty acid transporters (fatty acid binding proteins, FABPs) FABP1 and FABP2, the ATP-binding cassettes (ABCs) ABCB1A and ABCC2, the amino acid/peptide transporters SLC3A1 and SLC15A1, the glucose transporters SLC5A1, SLC2A2 and SLC2A5, the organic anion transporter SLC22A9 and the phosphate transporters SLC20A1 and SLC37A4. In mice, a similar profile was observed with high expression of the glucose transporters SLC5A1 and SLC2As, the fatty acid transporters FABP1 and FABP2, the MDR/MRP transporters ABCB1A and ABCC2 and the phosphate transporter SLC37A4. However, the overall data reveal diverse transcriptomic profiles of the intestinal transporters of dogs and mice. Therefore, the current database may be useful for comparing the intestinal transport systems of dogs with those of mice to better evaluate xenobiotics.

Citing Articles

Species Differences in Metabolism of Soluble Epoxide Hydrolase Inhibitor, EC1728, Highlight the Importance of Clinically Relevant Screening Mechanisms in Drug Development.

McReynolds C, Yang J, Guedes A, Morisseau C, Garcia R, Knych H Molecules. 2021; 26(16.

PMID: 34443621 PMC: 8399023. DOI: 10.3390/molecules26165034.


Molecular targeting of FATP4 transporter for oral delivery of therapeutic peptide.

Hu Z, Nizzero S, Goel S, Hinkle L, Wu X, Li C Sci Adv. 2020; 6(14):eaba0145.

PMID: 32270048 PMC: 7112756. DOI: 10.1126/sciadv.aba0145.


Exploring Canine-Human Differences in Product Performance. Part II: Use of Modeling and Simulation to Explore the Impact of Formulation on Ciprofloxacin In Vivo Absorption and Dissolution in Dogs.

Martinez M, Mistry B, Lukacova V, Lentz K, Polli J, Hoag S AAPS J. 2017; 19(3):712-726.

PMID: 28265981 DOI: 10.1208/s12248-017-0055-y.

References
1.
Sandusky G, Mintze K, Pratt S, Dantzig A . Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology. 2002; 41(1):65-74. DOI: 10.1046/j.1365-2559.2002.01403.x. View

2.
Schaffer J, Lodish H . Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell. 1994; 79(3):427-36. DOI: 10.1016/0092-8674(94)90252-6. View

3.
El Kouni M . Trends in the design of nucleoside analogues as anti-HIV drugs. Curr Pharm Des. 2002; 8(8):581-93. DOI: 10.2174/1381612024607171. View

4.
Shin H, Kim H, Cho H, Yi H, Cho S, Lee D . Comparative gene expression of intestinal metabolizing enzymes. Biopharm Drug Dispos. 2009; 30(8):411-21. DOI: 10.1002/bdd.675. View

5.
Wang W, Jiang J, Ballard C, Wang B . Prodrug approaches to the improved delivery of peptide drugs. Curr Pharm Des. 1999; 5(4):265-87. View